- Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a monotherapy and in several combination studies
- Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®+, second-generation TKI Giotrif®/Gilotrif®**, anti-angiogenic agents Vargatef®*** and Avastin®, and Boehringer Ingelheim's investigational IGF mAb BI 836845****
- Accelerated trial programme underway with ELUXA 1 trial fully enrolled; additional Phase III trials to start soon
Dans la même rubrique :
Jeudi 11 Septembre 2025 - 10:12 Tchad : ARCHI, fer de lance de la microfinance islamique au Tchad |
Mardi 29 Juillet 2025 - 15:30 Burkina Faso : 6 millions d’euros pour développer un projet solaire à Dédougou |